… can inhibit PI3K and/or mTOR signaling in tumor … PI3K/AKT/mTOR pathway commonly
activated in tumor cells, but VEGF binding to receptors on endothelial cells stimulates this pathway …

… The comprehensive PI3K/AKT/mTOR pathway described in this report covers 25 drug
categories, which include 104 molecularly targeted therapeutic agents undergoing clinical …

… Finally, we discuss the issues and limitations involved with targeting the PI3K–AKT–mTOR
pathway, and predict what the future may hold for these novel anticancer therapeutics. …

… Inhibition of mTOR in patients with cancer became more feasible after the development of …
The PI3K/Akt/mTOR pathway Signaling through the PI3K/Akt/mTOR pathway begins with the …

… and mTOR inhibitors (rapamycin, CCI-779, RAD-001) and discuss strategies to combine these
pathway … We will also discuss how the complex regulation of the PI3K/Akt/mTOR pathway …

… PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy
found in key pathway … Novel approaches to PI3K/AKT/mTOR pathway inhibition together …

It is well established that the PI3K pathway plays a central role in various cellular processes
that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of …

… In conclusion, the investigation of mutations that occur in the PI3K/AKT/mTOR signaling
pathway, but also of its inhibitors, may be a real benefit for patients diagnosed with breast cancer…

… PI3K OR AKT OR mTOR’ and ‘osteoarthritis’. This review highlights the role of PI3K/AKT/mTOR
signaling … , and discusses how this signaling pathway affects development of the disease. …

… they could be regarded as a single, unique pathway. In this paper, after a general overview
… pathways, we address the present status of the development of specific PI3K, Akt, and mTOR …